{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T07:44:54Z","timestamp":1794296694699,"version":"4.9.0"},"reference-count":54,"publisher":"Society of Nuclear Medicine","issue":"Supplement 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.2967\/jnumed.121.263195","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T12:11:10Z","timestamp":1654085470000},"page":"13S-19S","source":"Crossref","is-referenced-by-count":278,"title":["The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review"],"prefix":"10.2967","volume":"63","author":[{"given":"Marianne","family":"Chapleau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Iaccarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Soleimani-Meigooni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil D.","family":"Rabinovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"2022060616200896000_63.Supplement_1.13S.1","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-019-0333-5"},{"key":"2022060616200896000_63.Supplement_1.13S.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.003"},{"key":"2022060616200896000_63.Supplement_1.13S.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2016.01.028"},{"key":"2022060616200896000_63.Supplement_1.13S.4","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww027"},{"key":"2022060616200896000_63.Supplement_1.13S.5","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20009"},{"key":"2022060616200896000_63.Supplement_1.13S.6","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2018.9"},{"key":"2022060616200896000_63.Supplement_1.13S.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0909142"},{"key":"2022060616200896000_63.Supplement_1.13S.8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1017\/S109285291600047X","article-title":"Approach to atypical Alzheimer\u2019s disease and case studies of the major subtypes","volume":"22","author":"Dickerson","year":"2017","journal-title":"CNS Spectr."},{"key":"2022060616200896000_63.Supplement_1.13S.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-009-0182-4"},{"key":"2022060616200896000_63.Supplement_1.13S.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"2022060616200896000_63.Supplement_1.13S.11","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the international working group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol."},{"key":"2022060616200896000_63.Supplement_1.13S.12","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1056\/NEJMp2111320","article-title":"Controversy and progress in Alzheimer\u2019s disease: FDA approval of aducanumab","volume":"385","author":"Rabinovici","year":"2021","journal-title":"N Engl J Med."},{"key":"2022060616200896000_63.Supplement_1.13S.13","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv112"},{"key":"2022060616200896000_63.Supplement_1.13S.14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nicl.2016.11.008","article-title":"Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort","volume":"13","author":"Seo","year":"2016","journal-title":"Neuroimage Clin."},{"key":"2022060616200896000_63.Supplement_1.13S.15","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21164"},{"key":"2022060616200896000_63.Supplement_1.13S.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2014.07.003"},{"key":"2022060616200896000_63.Supplement_1.13S.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.09.001"},{"key":"2022060616200896000_63.Supplement_1.13S.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70142-4"},{"key":"2022060616200896000_63.Supplement_1.13S.19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","article-title":"Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density","volume":"72","author":"Curtis","year":"2015","journal-title":"JAMA Neurol."},{"key":"2022060616200896000_63.Supplement_1.13S.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.02.004"},{"key":"2022060616200896000_63.Supplement_1.13S.21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.4668"},{"key":"2022060616200896000_63.Supplement_1.13S.22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","article-title":"Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum","volume":"79","author":"Jansen","year":"2022","journal-title":"JAMA Neurol."},{"key":"2022060616200896000_63.Supplement_1.13S.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.6669"},{"key":"2022060616200896000_63.Supplement_1.13S.24","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jalz.2018.03.005","article-title":"Estimation of lifetime risks of Alzheimer\u2019s disease dementia using biomarkers for preclinical disease","volume":"14","author":"Brookmeyer","year":"2018","journal-title":"Alzheimers Dement."},{"key":"2022060616200896000_63.Supplement_1.13S.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.008"},{"key":"2022060616200896000_63.Supplement_1.13S.26","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1017\/S1355617720000934","article-title":"Identifying sensitive measures of cognitive decline at different clinical stages of Alzheimer\u2019s disease","volume":"27","author":"Jutten","year":"2021","journal-title":"J Int Neuropsychol Soc."},{"key":"2022060616200896000_63.Supplement_1.13S.27","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1001\/jamaneurol.2018.0894","article-title":"Use of flutemetamol F 18-labeled positron emission tomography and other biomarkers to assess risk of clinical progression in patients with amnestic mild cognitive impairment","volume":"75","author":"Wolk","year":"2018","journal-title":"JAMA Neurol."},{"key":"2022060616200896000_63.Supplement_1.13S.28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000431"},{"key":"2022060616200896000_63.Supplement_1.13S.29","doi-asserted-by":"crossref","first-page":"e662","DOI":"10.1212\/WNL.0000000000011222","article-title":"Association of beta-amyloid level, clinical progression, and longitudinal cognitive change in normal older individuals","volume":"96","author":"van der Kall","year":"2021","journal-title":"Neurology."},{"key":"2022060616200896000_63.Supplement_1.13S.30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.2000"},{"key":"2022060616200896000_63.Supplement_1.13S.31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.4669"},{"key":"2022060616200896000_63.Supplement_1.13S.32","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31823b9c5e"},{"key":"2022060616200896000_63.Supplement_1.13S.33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/ana.25968","article-title":"Diagnostic accuracy of amyloid versus 18F-fluorodeoxyglucose positron emission tomography in autopsy-confirmed dementia","volume":"89","author":"Lesman-Segev","year":"2021","journal-title":"Ann Neurol."},{"key":"2022060616200896000_63.Supplement_1.13S.34","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.185017"},{"key":"2022060616200896000_63.Supplement_1.13S.35","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s00259-020-05187-x","article-title":"Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives","volume":"48","author":"Cotta Ramusino","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022060616200896000_63.Supplement_1.13S.36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000478007","article-title":"Effectiveness of florbetapir PET imaging in changing patient management","volume":"44","author":"Pontecorvo","year":"2017","journal-title":"Dement Geriatr Cogn Disord."},{"key":"2022060616200896000_63.Supplement_1.13S.37","doi-asserted-by":"crossref","unstructured":"Rabinovici G Iaccarino L La Joie R . Amyloid and tau PET in sporadic early\u2010onset Alzheimer\u2019s disease: preliminary results from LEADS: LEADS: sporadic early\u2010onset Alzheimer\u2019s disease in the spotlight. Alzheimers Dement. 2020;16:1\u20134.","DOI":"10.1002\/alz.041613"},{"key":"2022060616200896000_63.Supplement_1.13S.38","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamaneurol.2018.1346","article-title":"Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE project","volume":"75","author":"de Wilde","year":"2018","journal-title":"JAMA Neurol."},{"key":"2022060616200896000_63.Supplement_1.13S.39","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jalz.2018.09.003","article-title":"AMYPAD diagnostic and patient management study: rationale and design","volume":"15","author":"Frisoni","year":"2019","journal-title":"Alzheimers Dement."},{"key":"2022060616200896000_63.Supplement_1.13S.40","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0485-0"},{"key":"2022060616200896000_63.Supplement_1.13S.41","doi-asserted-by":"crossref","first-page":"e12190","DOI":"10.1002\/dad2.12190","article-title":"P-tau\/Abeta42 and Abeta42\/40 ratios in CSF are equally predictive of amyloid PET status","volume":"13","author":"Campbell","year":"2021","journal-title":"Alzheimers Dement (Amst)."},{"key":"2022060616200896000_63.Supplement_1.13S.42","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww015"},{"key":"2022060616200896000_63.Supplement_1.13S.43","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008081"},{"key":"2022060616200896000_63.Supplement_1.13S.44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13195-021-00911-7","article-title":"Performance of the plasma Abeta42\/Abeta40 ratio, measured with a novel HPLC-MS\/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort","volume":"13","author":"Jang","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"2022060616200896000_63.Supplement_1.13S.45","first-page":"34","article-title":"Plasma Abeta42\/40 ratio detects early stages of Alzheimer\u2019s disease and correlates with CSF and neuroimaging biomarkers in the AB255 study","volume":"6","author":"P\u00e9rez-Grijalba","year":"2019","journal-title":"J Prev Alzheimers Dis."},{"key":"2022060616200896000_63.Supplement_1.13S.46","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00214-3"},{"key":"2022060616200896000_63.Supplement_1.13S.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0762-2"},{"key":"2022060616200896000_63.Supplement_1.13S.48","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol (Berl)."},{"key":"2022060616200896000_63.Supplement_1.13S.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadm.2017.04.007"},{"key":"2022060616200896000_63.Supplement_1.13S.50","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med."},{"key":"2022060616200896000_63.Supplement_1.13S.51","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-Abeta protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"2022060616200896000_63.Supplement_1.13S.52","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat Med."},{"key":"2022060616200896000_63.Supplement_1.13S.53","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.12.1791"},{"key":"2022060616200896000_63.Supplement_1.13S.54","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3390\/molecules25040977","article-title":"PET radiopharmaceuticals for Alzheimer\u2019s disease and Parkinson\u2019s disease diagnosis, the current and future landscape","volume":"25","author":"Uzuegbunam","year":"2020","journal-title":"Molecules."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.121.263195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T03:38:53Z","timestamp":1727321933000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.121.263195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":54,"journal-issue":{"issue":"Supplement 1","published-online":{"date-parts":[[2022,6,1]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.2967\/jnumed.121.263195"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.121.263195","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}